statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AJ Mast / Bloomberg via Getty Images

 Key TakeawaysEli Lilly is set to report earnings Tuesday as investors and analysts expect weight-loss drug demand to continue boosting the company's revenue...

What You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday

Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1...

Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma

Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits.
read more...

Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential...

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

The Food and Drug Administration said this week that more doses of Eli Lilly's popular diabetes and weight loss drugs will be in limited supply through the end of June. Johnson & Johnson's recent...

Fake Ozempic sites, more Zepbound shortage, and J&J 's sales miss: Pharma news roundup

Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025.
read more...

Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025

Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years

Zepbound drugmaker Eli Lilly is working to increase its weight loss drug supply. But some steps to get there, including building a new plant, will take months to execute...

As Zepbound shortage grows, Eli Lilly says no immediate end is in sight

Eli Lilly's weight loss-related drug Zepbound could potentially be used to reduce the severity of sleep apnea in adults with obesity, according to a recent study. Results of a phase three clinical...

Eli Lilly's weight loss drug reduces sleep apnea, study shows

Eli Lilly's Zepbound showed promise to treat obstructive sleep apnea in two late-stage trials. It's yet another reason to stay invested in the drugmaker...

Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Volume	2.01M
52-Wk High	$800.78
52-Wk Low	$392.26

LLY Lilly(Eli) & Co

About

Feed

News

Sentiment

Earnings

Fundamentals